Clinical Trials
192 trialsSTARTRK-2
Hoffmann-La Roche
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
University of Colorado, Denver
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
ReRT
The New York Proton Center
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
PORTICO
Luzerner Kantonsspital
ONE TEAM
Duke University
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
TAGNOT
Kidney Cancer Research Bureau
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
PAVO
Tempus AI
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
ENGAGE
Maastricht Radiation Oncology
EARN
Washington University School of Medicine
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
EDHITO
Institut Cancerologie de l'Ouest
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
FASCINATE
The Netherlands Cancer Institute
JUMP
Brigham and Women's Hospital
START-001
Marengo Therapeutics, Inc.